Register Now or Lose the EU Market

EU's EUDAMED database goes mandatory 28 May 2026, forcing all medical device makers to register or risk losing market access

21 May 2026

Europe's medical device traceability rules are no longer a future obligation. From 28 May 2026, EUDAMED, the EU's centralised medical device database, becomes compulsory for all manufacturers, importers, and authorised representatives operating under the Medical Device Regulation and In Vitro Diagnostic Regulation.

Four modules are now required: Actor Registration, UDI/Device Registration, Notified Bodies and Certificates, and Market Surveillance. No extensions remain. Any new device must be registered before it reaches the EU market.

Commission Decision (EU) 2025/2371, published in November 2025, confirmed the mandate and activated a fixed six-month transition under Regulation (EU) 2024/1860. Devices already on market before 28 May carry a secondary window, with full registration required by 28 November 2026. Two further modules, Vigilance and Clinical Investigations, follow once officially declared functional.

For sterilised device manufacturers, the operational impact is immediate. Single-use instruments, sterile implants, and reprocessed surgical tools must carry clean, structured Unique Device Identifier data tied directly to their EUDAMED records. Industry analysts consistently flag data quality, not the registration step itself, as the primary risk. Manufacturers running fragmented ERP systems or manual inventory tracking face the greatest exposure to incomplete or non-conforming submissions.

Noncompliance carries serious consequences. Failing to meet EUDAMED requirements risks losing access to one of the world's largest medical device markets. Under Article 10a of Regulation (EU) 2024/1860, manufacturers must also report supply disruptions that could harm patients, making accurate, real-time device records a matter of both regulatory obligation and patient safety.

Proposed MDR simplification measures, tabled by the European Commission in December 2025, remain in early legislative stages. Relief under that proposal will not reduce current EUDAMED obligations before late 2026 at the earliest.

Digital traceability is now the foundation of device safety in Europe. For sterilisation sector manufacturers, where chain-of-custody integrity directly determines patient outcomes, this shift presents a clear opportunity: build the compliance infrastructure now, and turn regulatory readiness into a durable competitive advantage.